• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Inhibikase Therapeutics Inc (NQ: IKT )

    2.310 +0.300 (+14.93%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 197,811
    Open 2.020
    Bid (Size) 2.250 (2)
    Ask (Size) 2.340 (1)
    Prev. Close 2.010
    Today's Range 1.960 - 2.387
    52wk Range 0.8500 - 3.820
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
    From Inhibikase Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga

    Performance

    YTD
    +73.45%
    +73.45%
    1 Month
    +9.48%
    +9.48%
    3 Month
    +68.61%
    +68.61%
    6 Month
    +26.23%
    +26.23%
    1 Year
    +151.09%
    +151.09%

    More News

    Read More
    This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
    Via Benzinga
    Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
    From Inhibikase Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Dow Surges 350 Points; US Crude Oil Stocks Increase
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Crude Oil Edges Lower; US Wholesale Inventories Rise 0.1% In August
    Via Benzinga
    Exposures Fossil Fuels
    Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today
    Via Benzinga
    Dow Jumps Over 100 Points; Helen Of Troy Posts Upbeat Q2 Results
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
    From Inhibikase Therapeutics
    Via GlobeNewswire
    IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
    From Inhibikase Therapeutics
    Via GlobeNewswire
    IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.